nadofaragene firadenovec

**Nadofaragene firadenovec** is a non-replicating recombinant adenovirus type 5 vector-based intravesical gene therapy that delivers the human interferon alfa-2b gene to bladder urothelial cells. Local transgene expression produces interferon alfa-2b, activating type I interferon signaling and promoting antitumor antiproliferative and immune-mediated effects. It is marketed in the United States as **Adstiladrin** for adults with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The product is administered as a 75 mL intravesical suspension once every three months. ([fda.gov](https://www.fda.gov/media/164029/download))

Brand names

Adstiladrin

Other names

nadofaragene firadenovec-vncgrAd-IFN/Syn3Instiladrin